# 18F-Flutemetamol and Plaque Vulnerability

> **NCT03291093** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Maastricht University Medical Center** · enrollment: 25 (estimated)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** 18F-Flutemetamol PET/MRI

## Key facts

- **NCT ID:** NCT03291093
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2019-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03291093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03291093, "18F-Flutemetamol and Plaque Vulnerability". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03291093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*